Top 50 Medical Startup Investors in Denmark (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
BioInnovation Institute
VC Fund
|
14 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Debt Financing | Biotechnology, Medical, Health Care | $516k–$5.2M |
|
Novo Holdings
VC Fund
|
13 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9M–$130M |
|
Export and Investment Fund
VC Fund
|
8 | Denmark, United States, United Kingdom | Seed, Series A | Software, Biotechnology, Health Care | $390k–$84M |
|
Vaekstfonden
VC Fund
|
6 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $440k–$4.6M |
|
Forbion Capital Partners
VC Fund
|
4 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $15M–$176M |
|
Crowberry Capital
VC Fund
|
3 | Iceland, Denmark, Finland | Seed, Series A, Pre-Seed | Software, Gaming, Health Care | $1k–$17M |
|
Sunstone Life Science Ventures
VC Fund
|
3 | Denmark, Sweden, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $5.5M–$52M |
|
Omega Funds
VC Fund
|
3 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Seed Capital
VC Fund
|
3 | Denmark, United States, United Kingdom | Seed, Series A | Software, Health Care, SaaS | $515k–$17M |
|
Bioqube Ventures
VC Fund
|
3 | United States, France, Norway | Seed, Series A, Series B | Biotechnology, Therapeutics, Life Science | $4M–$108M |
|
VentureFriends
VC Fund
|
2 | Greece, United Kingdom, United States | Seed, Series A, Pre-Seed | FinTech, Software, E-Commerce | $105k–$25M |
|
PSV
VC Fund
|
2 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $88k–$4.7M |
|
Innovation Fund Denmark
VC Fund
|
2 | Denmark, United States | Grant, Pre-Seed, Seed | Software, Biotechnology, SaaS | $22k–$1.6M |
|
Sagitta Ventures
VC Fund
|
2 | Denmark, Sweden | Series A, Series B | Health Care, Apps, Mobile | $11M–$20M |
|
CAPNOVA
VC Fund
|
2 | Denmark, United States, India | Seed, Pre-Seed | Software, Information Technology, B2B | $147k–$2.4M |
|
People Ventures
VC Fund
|
2 | Denmark, Sweden, United States | Seed, Pre-Seed, Series A | Software, Health Care, Internet of Things | $1.1M–$21M |
|
Wellcome Trust
VC Fund
|
2 | United States, United Kingdom, France | Grant, Series C | Biotechnology, Health Care, Medical | $1.3M–$127M |
|
North Ventures
VC Fund
|
2 | Denmark, Norway | Series A, Seed | Medical, Software, Health Care | $5.8M–$20M |
|
Antler
VC Fund
|
2 | Singapore, Australia, United Kingdom | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $104k–$29M |
|
Industrifonden
VC Fund
|
2 | Sweden, United States, Denmark | Series A, Seed | Software, Biotechnology, Information Technology | $1.1M–$21M |
|
M Ventures
VC Fund
|
1 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Eli Lilly
VC Fund
|
1 | United States, United Kingdom, Canada | Series A, Series B | Biotechnology, Health Care, Medical | |
|
Biofund
VC Fund
|
1 | Canada, Denmark, Russian Federation | Seed | Genetics, Medical, Health Care | |
|
Cormorant Asset Management
VC Fund
|
1 | United States, China, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Medical | |
|
VIB
VC Fund
|
1 | Belgium, Brazil, Denmark | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.2M–$84M |
|
Morten Strunge
Angel
|
1 | Denmark, United States | Seed, Pre-Seed | Fashion, E-Commerce, Beauty | |
|
Bhavik Bajaj
Angel
|
1 | United States, Switzerland, United Kingdom | Pre-Seed, Seed, Angel | Information Technology, Software, FinTech | $15k–$3M |
|
V-Bio Ventures
VC Fund
|
1 | Belgium, France, United States | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.2M–$88M |
|
Sanofi Ventures
VC Fund
|
1 | United States, United Kingdom, France | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $9M–$150M |
|
VF Venture
VC Fund
|
1 | Denmark, United Kingdom, Iceland | Seed, Series A | Software, SaaS, Biotechnology | $1.2M–$22M |
|
Roche Venture Fund
VC Fund
|
1 | United States, United Kingdom, Spain | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5M–$125M |
|
BankInvest Biomedical Venture
VC Fund
|
1 | Denmark, United Kingdom, France | Series B, Series C | Biotechnology, Health Care, Medical | $6.1M–$14M |
|
Crista Galli Ventures
VC Fund
|
1 | United Kingdom, United States, Sweden | Seed, Pre-Seed, Series A | Health Care, Medical, Wellness | $655k–$14M |
|
EISMEA
VC Fund
|
1 | Spain, Switzerland, United Kingdom | Grant, Seed | Biotechnology, Software, Health Care | $55k–$2.7M |
|
Polaris Partners
VC Fund
|
1 | United States, Ireland, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $4.5M–$107M |
|
CBC Investment Group
VC Fund
|
1 | Sweden, Denmark, Germany | Seed, Series B | Software, Biotechnology, SaaS | |
|
LS Polaris Innovation Fund
VC Fund
|
1 | United States, Denmark | Series A, Series B | Biotechnology, Medical, Biopharma | $22M–$83M |
|
Dansk Erhvervsinvestering
VC Fund
|
1 | Denmark | Medical, Health Care, Biotechnology | ||
|
Inkef
VC Fund
|
1 | The Netherlands, United States, Germany | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $2.2M–$88M |
|
Sofinnova Partners
VC Fund
|
1 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$120M |
|
Droia Ventures
VC Fund
|
1 | United States, Belgium, The Netherlands | Series A, Series B, Series C | Biotechnology, Medical, Therapeutics | $15M–$125M |
|
Bossa Invest
VC Fund
|
1 | Brazil, United States, Mexico | Seed, Pre-Seed | Software, Information Technology, Financial Services | $50k–$5M |
|
LF Investment
VC Fund
|
1 | Denmark | Medical, Wellness, Health Care | ||
|
LSP BioVentures
VC Fund
|
1 | United States, Germany, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $5.3M–$176M |
|
Roland Berger
Angel
|
1 | Germany, Denmark, Switzerland | Series A, Series B | Financial Services, Information Services, Apps | $4.9M–$30M |
|
DigitalDx Ventures
VC Fund
|
1 | United States, Canada, Denmark | Series A, Seed | Biotechnology, Health Care, Medical | $3.5M–$18M |
|
Novo Ventures
VC Fund
|
1 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $8.5M–$143M |
|
European Investment Bank
VC Fund
|
1 | France, Germany, The Netherlands | Debt Financing, Post-IPO Debt | Biotechnology, Health Care, Energy | $16M–$658M |
|
Danske Bank
VC Fund
|
1 | Sweden, Denmark, Finland | Post-IPO Debt, Debt Financing | Manufacturing, Energy, Biotechnology | $3.3M–$3B |
|
GoBeyond
VC Fund
|
1 | Switzerland, Germany, United Kingdom | Seed, Series A | Information Technology, Medical, Software | $544k–$10M |
| Access all 132 investors in Denmark Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Debt Financing
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 73
- Round size: Pre-Seed $516k–$5.2M; Debt Financing $549k–$1.4M; Convertible Note $549k–$1.5M
- Lead/follow: 90% lead, 10% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 335
- Round size: Series A $9M–$120M; Series B $12M–$130M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- AlloCure — AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany.The company isdedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany.
- PTC Therapeutics — Translating Science. Transforming Lives.
- Freeline — A leading biotechnology company focused on innovative liver directed gene therapies for bleeding disorders and other debilitating, chronic diseases
Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 119
- Round size: Seed $390k–$11M; Series A $4.7M–$84M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Woba — Woba is a SaaS aiming to support a stress-free work environment and minimise sick leave.
- Embankment — Dedicated to AIFs. Driven by technology, delivered by domain experts
- Landfolk — Landfolk is the new marketplace for the special holiday homes that are hidden around the country. We have hand-picked every single cottage, where there are proud and passionate hosts, who love their holiday homes, but also like to share it with others.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 196
- Round size: Seed $810k–$4.6M; Pre-Seed $440k–$1.2M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Captego — Unique, high-speed field data capture. Empower your inspectors & surveyors with our unique collection app. Benefit from high quality data to automate reports and data insights.
- LastSwab — LastSwab launched May 2019 through the crowdfunding platform Kickstarter. At $16 a swab, LastSwab is meant to last at least 1,000 uses and is the easy-to-clean, reusable alternative to the abundant waste caused by single-use swabs around the globe. The tip of the swab is made from medical silicone and nylon and comes in a biodegradable case made ofa corn-based material. LastSwab can be easily cleaned using soap and water and is also dishwasher safe. It comes in a standard swab for cleaning and a pointed swab for makeup application. Be the change and #SwabYourHabits.
- Donkey Republic — Donkey Republic is leading bike share service in Europe with footprint in more than 10 key cities in Europe. We operate our locations with partners, and use custom-branded bikes. Our software backbone is developed by us with unique features that ensure we respect public space with our hub-centric service model. At the same time, we maximizepredictability of bike availability and convenience. We pride ourselves in service innovation.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 187
- Round size: Series A $16M–$176M; Series B $15M–$155M; Series C $19M–$113M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
- Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.
Show more...Investment focus
- Industry: Software, Gaming, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Iceland, Denmark, Finland
Investor stats
- Total investments: 48
- Round size: Seed $1.6M–$4.7M; Pre-Seed $1k–$1.3M; Series A $5.7M–$17M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Prescriby — Prescriby is a digital treatment system developer to combat the opioid crisis by improving prescription safety and monitoring.Prescriby features a treatment generator and dashboard monitor to simplify complex health information, allowing clinics to give individualized data-driven therapies and safer monitoring for their customers.
- Dreamdata — Dreamdata is a B2B Revenue Attribution Platform that gathers, joins, cleans all revenue-related data to present transparent, actionable analysis of what drives B2B revenue. The ultimate B2B multi-touch attribution tool for multi-techstack businesses.
- Mainframe Industries — Mainframe Industries is a Reykjavik, Iceland and Helsinki, Finland-based startup working on the development of an open world, social sandbox MMO for cloud gaming.The company will will work on an open-world, social sandbox MMO specifically designed for cloud gaming, with cross-platform play across mobile, PC, and TV. Mainframe believes that thepromise of friction-free access from social networks and streaming platforms on the device of your choice will greatly expand the creative canvas for game developers.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 56
- Round size: Series A $5.5M–$43M; Series B $9.6M–$52M
- Lead/follow: 14% lead, 86% follow
- Last fund: May invest from a new fund soon — raised $94M in 2019
Portfolio highlights
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 149
- Round size: Series A $16M–$197M; Series B $35M–$162M; Series C $14M–$208M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
- NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 186
- Round size: Seed $515k–$5M; Series A $3.5M–$17M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $73M in 2021
Portfolio highlights
- Cardlay — Build your own white-label card and expense management solution with Cardlay. Our platform helps banks, fleets, and tech partners launch modern spend management solutions fast.
- Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
- Odendo — On Odendo you can make a great deal on exciting products while supporting a good cause
Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Life Science
- Stage:Seed, Series A, Series B
- Geography: United States, France, Norway
Investor stats
- Total investments: 18
- Round size: Seed $5.7M–$21M; Series A $4M–$76M; Series B $23M–$108M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Commit Biologics — Add a description for facebook
- Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!VentureFriends is a venture capital fund that invests in tech-enabled companies. VentureFriends (VF) is a venture capital fund specialising in seed stage startups. VF seeks to invest in tech-enabled B2C and B2B startups that can develop a sustainable moat over time and have a sweet spot for PropTech, FinTech, Marketplaces, and SaaS. The fundtypically invests between €0.3M - €2.5M and can follow on up to a total of €5 - 10M. VentureFriends invests predominantly in Europe and is founded by ex-entrepreneurs and angel investors, thus having an entrepreneurial and founder-friendly philosophy.
Show more...Investment focus
- Industry: FinTech, Software, E-Commerce
- Stage:Seed, Series A, Pre-Seed
- Geography: Greece, United Kingdom, United States
Investor stats
- Total investments: 121
- Round size: Seed $424k–$6.7M; Pre-Seed $105k–$3M; Series A $2.7M–$25M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $110M in 2021
Portfolio highlights
- Capalo AI — We maximize the value of your energy storage systems. Now and in the future.
- Cube AI — Cube AI provides software that applies machine learning to business workflows and data. The platform enables creation of AI assistants, connections to internal data sources, and task automation through APIs and integrations. Capabilities include natural language processing for classification, summarization, and question answering, retrieval overdocuments and knowledge bases, and analytics that surface insights from structured and unstructured data. Solutions cover use cases such as customer support, sales enablement, lead routing, and document processing, helping teams reduce manual steps and standardize processes. Tooling includes SDKs, dashboards, and monitoring to deploy, observe, and refine models in production.
- Proportunity — Proportunity is a technology-driven mortgage lender. The company pushes the edge on real estate data-driven investment insights. It uses machine learning to accurately forecast house prices and up-and-coming areas, providing loans to buyers looking to purchase homes in forecasted high-growing areas.Vadim Toader and Stefan Boronea startedProportunity in 2016, which is headquartered in London, England.
PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV Hafnium, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment. Together, we can punch above our weight.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 138
- Round size: Seed $500k–$4.7M; Pre-Seed $88k–$2.5M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $42M in 2020
Portfolio highlights
- Viio — Oveo creates cloud-based software that enables any company in any industry to easily discover, manage, optimise and secure all SaaS usage from one platform.We believe employees should be able to enjoy work, be agile, move fast and in turn become more innovative on behalf of the companies they work for. In a subscribed economy a “SaaS-Poweredworkplace” is the enabling foundation to make that vision come true and at Oveo we proud to contribute by making SaaS usage more transparent, manageable and secure. Theircloud-based software enable companies to easily push this transformation and as SaaS adoption continues to skyrocket we will be right here with you - building the platform to manage and optimize the lifecycle of your SaaS applications.
- Woba — Woba is a SaaS aiming to support a stress-free work environment and minimise sick leave.
- Legal Monster — Openli makes privacy transparent. Get control of your data processors and keep your DPAs up to date. Build trust and close deals faster all with Openli.
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Grant, Pre-Seed, Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 89
- Round size: Seed $66k–$1.3M; Grant $22k–$1.1M; Pre-Seed $64k–$1.6M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Prezio — Prezio is an electricity tariff data API for Europe. We aggregate, structure, and serve real-time and historical electricity pricing data - spot prices, retail tariffs, and grid fees - so energy applications don't have to build and maintain that data infrastructure themselves. Typical customers are developers and product teams building EVsmart charging, heat pump control, home batteries, and solar optimization tools - anything that needs to know what electricity actually costs, right now or over time, across European markets.
- SureShot — SureShot empowers you and your audience to become video co-creators. With our cutting-edge AI, capture, edit, and share electrifying videos that amplify the essence of every event.
- AlterEcho — AlterEcho is redefining aseptic manufacturing by decoupling human operators from cleanroom environments through First-Person View Remote Robotic Embodiment. Instead of direct intervention, operators control precision robotics remotely via first-person-view headsets and motion controllers, maintaining the dexterity and adaptability of humanoversight while eliminating contamination risks. This paradigm shift enables pharmaceutical manufacturers to enhance scalability, optimize facility layouts, and future-proof production against labor shortages and regulatory pressures. Unlike conventional automation, which struggles with edge cases and lengthy validation cycles, AlterEcho keeps human decision-making in the loop while generating the operational data and infrastructure that could enable more autonomous biomanufacturing in the future. A Techstars-backed venture, AlterEcho is not just iterating on aseptic workflows - it’s reengineering the fundamental relationship between humans and pharmaceutical production.
Sagitta Ventures invests in early-stage companies in the Nordics and provides long-term capital backing for well-managed businesses that are seeking minority investors without a defined exit horizon.
Show more...Investment focus
- Industry: Health Care, Apps, Mobile
- Stage:Series A, Series B
- Geography: Denmark, Sweden
Investor stats
- Total investments: 5
- Round size: Series A $11M–$20M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Cerebriu — Cerebriu is a health tech company developing machine learning in medical imaging that improves workflow efficiency and quality in radiology.Its software solution Cerebriu Apollo achieves the company's aim by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of thediagnostic process. The company covers findings of the brain, starting with brain MRI, including stroke, bleeds, and tumors, following MS, dementia, and TBI in brain CT.
- Donkey Republic — Donkey Republic is leading bike share service in Europe with footprint in more than 10 key cities in Europe. We operate our locations with partners, and use custom-branded bikes. Our software backbone is developed by us with unique features that ensure we respect public space with our hub-centric service model. At the same time, we maximizepredictability of bike availability and convenience. We pride ourselves in service innovation.
- Heart Aerospace — Heart’s mission is to create the fastest, most affordable and sustainable transportation for regional travel to every corner of the world. Their first aircraft is the ES-19, a nineteen-passenger airliner with an operating range of 400 km. Heart's goal is to have the aircraft certified for commercial operation by 2026.
They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.
Show more...Investment focus
- Industry: Software, Information Technology, B2B
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, India
Investor stats
- Total investments: 24
- Round size: Seed $147k–$2.4M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Ulobby — Ulobby is an automated tool for stakeholder management and political monitoring
- Mechanic Miner — Mechanic Miner is a 2D construction/survival game with mechanical steam-powered machines. You are stranded on a strange and forbidding planet, where survival is made difficult by hostile animals and plant life. From your home world you did bring a multitool, which is able to craft any kind of machine part - provided the requisite rawmaterials can be found. Relying solely on the technology you brought, you set out to explore a whole world. You can progress through the game by acquiring new types of steam-powered technology elements, that are necessary to delve deeper into the diverse biomes of the planet, and perhaps, ultimately, discover the means to escape. You can construct any kind of machine of your own design - and any kind of machine can be simulated by the game's physics engine - and of course, designs can be shared with your friends.
- ResoTher Pharma — ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role.
Backing founders with people, money and presence | People Ventures
Show more...Investment focus
- Industry: Software, Health Care, Internet of Things
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 34
- Round size: Seed $1.1M–$19M; Pre-Seed $1.5M–$1.6M; Series A $6.3M–$21M
- Lead/follow: 62% lead, 38% follow
Portfolio highlights
- Alrik — Turn your logistics into a competitive advantage and take control of your emissions. We help building material suppliers revolutionize their workflows.
- Klaay — Klaay provides a cloud-based compliance platform focused on automating SOC 2, ISO 27001, GDPR, and related regulatory processes. The company’s software uses AI to support tasks such as evidence collection, risk monitoring, policy management, and audit preparation. Its platform centralizes compliance controls, vendor management, and documentationinto a single system designed to streamline audit readiness. Klaay serves businesses that require structured compliance workflows and ongoing regulatory maintenance through automated and guided processes.
- Passendo — Passendo is the leading email ad server and platform for publishers and advertisers: unlock new revenue with powerful targeting and delivery.
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Grant, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 121
- Round size: Grant $1.3M–$8.9M; Series C $10M–$127M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $319M in 2018
Portfolio highlights
- System — System is a free, open, and living public resource that aims to explain how anything in the world is connected to everything else.
- Lario Therapeutics — Lario Therapeutics is a biopharmaceutical firm that develops precision therapeutics for epilepsy and neurological disorders.
- Ineffable Intelligence — Ineffable Intelligence develops machine learning systems that learn through interaction and experience. The company works on reinforcement learning approaches that allow models to improve by trial and error rather than relying on large human-generated datasets. Its core work centers on building a “superlearner,” a system designed to generateknowledge and skills by engaging with simulated or real environments.The organization develops algorithms and computational frameworks that support autonomous learning, experimentation, and decision-making processes. Its efforts involve designing AI models that can adapt, refine behavior, and solve complex problems through continuous feedback loops. The company’s research aims to expand how AI systems acquire knowledge and apply it across different domains.
North Ventures is a venture capital firm investing in technology-driven companies from Seed to Series A in Denmark and across the Nordics.
Show more...Investment focus
- Industry: Medical, Software, Health Care
- Stage:Series A, Seed
- Geography: Denmark, Norway
Investor stats
- Total investments: 7
- Round size: Series A $5.8M–$20M
- Lead/follow: 86% lead, 14% follow
Portfolio highlights
- Viio — Oveo creates cloud-based software that enables any company in any industry to easily discover, manage, optimise and secure all SaaS usage from one platform.We believe employees should be able to enjoy work, be agile, move fast and in turn become more innovative on behalf of the companies they work for. In a subscribed economy a “SaaS-Poweredworkplace” is the enabling foundation to make that vision come true and at Oveo we proud to contribute by making SaaS usage more transparent, manageable and secure. Theircloud-based software enable companies to easily push this transformation and as SaaS adoption continues to skyrocket we will be right here with you - building the platform to manage and optimize the lifecycle of your SaaS applications.
- QuadSAT — Develops radio frequency detection and geolocation payloads and software enabling electromagnetic spectrum control for defense operations.
- Cerebriu — Cerebriu is a health tech company developing machine learning in medical imaging that improves workflow efficiency and quality in radiology.Its software solution Cerebriu Apollo achieves the company's aim by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of thediagnostic process. The company covers findings of the brain, starting with brain MRI, including stroke, bleeds, and tumors, following MS, dementia, and TBI in brain CT.
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Singapore, Australia, United Kingdom
Investor stats
- Total investments: 1200
- Round size: Seed $196k–$5.8M; Pre-Seed $104k–$1.1M; Series A $4.6M–$29M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely actively investing — fresh fund, raised $72M in 2024
Portfolio highlights
- Casu — Connecting businesses with casual workers
- 48 Hours — 48HRS is a B2B startup that works as a bid reservation plugin for hotel industry loyalty members. 48 hours helps hotels improve occupancy rates, loyalty membership engagement, and challenge online travel agents.
- Geekzwolf — Blockchain-powered gaming hub platform that attract the real gamers in a way that gamers enjoy the most: Tournaments, quest hunting, and community
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Series A, Seed
- Geography: Sweden, United States, Denmark
Investor stats
- Total investments: 182
- Round size: Seed $1.1M–$6.3M; Series A $3.3M–$21M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- inRiver — Turn product data into a profit maker at every touchpoint with Inriver's market-leading PIM solution that powers the entire product journey.
- AnaCardio — AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
- Open Payments — Open Payments connects you to multiple banks through one single unified API. This removes the complexity and frictions of many diverse integrations
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 170
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
- Biolinq — Introducing a revolutionary platform for metabolic health.
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Lilly is a medicine company that puts health above all. Learn about our medicines, view condition support, find care, and much more.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 111
- Lead/follow: no public data
Portfolio highlights
- Excelsior Sciences — Rebuilding the World, From the Bottom Up
- Syndeio Biosciences — Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders.
- Affinia Therapeutics — Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines for people.
BIOFUND SpA, established by Fondazione Monte dei Paschi, Bank Monte dei Paschi , Finanziaria Senese di Sviluppo e Fidi Toscana, provides the initial seed capital for companies located in the incubator of Toscana Life Sciences in Siena.
Show more...Investment focus
- Industry: Genetics, Medical, Health Care
- Stage:Seed
- Geography: Canada, Denmark, Russian Federation
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- Exiqon — Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.
- RTM Diagnostika — Diagnostic microwave radio RTM-01-RESThe temperature and rate of growth of malignant tumorsCancer is the terrible disease of breast. That is why the full range of diagnostic measures in mammalogy aimed primarily at identifying it. It is known that the malignant tumor has a higher temperature compared with surrounding tissues. These data werefirst obtained Guture M. French scientist, who, after more than 550 invasive measurements demonstrated that malignancy is determined by its temperature is doubling time. Therefore, the most dangerous, rapidly growing tumors have a very high temperature. It is also known that thermal changes, usually preceded by structural changes. In particular, the thermal changes of the mammary glands come not a moment when the cancer reaches the required size, but much earlier. Studies have shown that even at the stage preceding the malignant growth, namely, when the cells have the expressed proliferation, accompanied by atypical changes, increases the density of microcapillary network, and as a consequence there is a local increase in temperature. Indisputable is the fact that patients with these changes have a high risk of malignancy. Many authors classify this condition as precancerous.The internal temperature - measure of angiogenesisIn 2003, Japanese scientists have shown that the temperature in the cancerous region determined by the density microcapillary network (microvessel density (MVD) [8]. This is the main parameter that characterizes angiogenesis. The density of the microcapillary network when proliferation atypia several times greater than the rate for normal tissues and characterizes the risk of malignancy. in addition, the microcapillary network density refers to the probability of transformation from noninvasive to invasive cancer, the probability of metastasis and tumor growth rate. Therefore, the internal temperature, as a measure of angiogenesis, provides important information about the development of cancer.
- Genizon BioSciences — Since 2005, we have helped thousands of people get the perfect domain name.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Switzerland
Investor stats
- Total investments: 157
- Lead/follow: no public data
Portfolio highlights
- Numab — Numab Therapeutics AG
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
- Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.
Strategic research in on life sciences and biotechnology
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Belgium, Brazil, Denmark
Investor stats
- Total investments: 23
- Round size: Seed $3.2M–$4.6M; Series A $6.8M–$84M; Series B $4.4M–$65M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Animab — Animal Health Company
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
- MRM Health NV — MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications.
Morten Strunge is the current Co-Founder of Nexta.io. He previously worked at Storytel AB as a Board Member.
Show more...Investment focus
- Industry: Fashion, E-Commerce, Beauty
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 5
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- UXCam — Our AI analyzes millions of data points to give you insights in under 30 seconds. Act fast. Lead with evidence. Impress stakeholders.
- Goodiebox — Goodiebox is an online cosmetic company that provides cosmetics and beauty products. It has developed a subscription business selling cosmetics and beauty products to women in the 15-35 years old range. They give both large international brands and smaller niche brands the opportunity to market their products directly to a specific target groupthat is interested in their products.The company mission is to create relationships between the beauty and cosmetics brands and consumers. It also distributes a box of cosmetics including products of various brands to women.Goodiebox was founded in 2012 and is headquartered in Copenhagen S, Capital Region, Denmark.
- SON OF A TAILOR — Custom tailored T-Shirts with Free Remake Guarantee. We use only the highest quality materials.
Bhavik Bajaj
Show more...Investment focus
- Industry: Information Technology, Software, FinTech
- Stage:Pre-Seed, Seed, Angel
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 74
- Round size: Seed $100k–$3M; Angel $15k–$1.6M; Pre-Seed $43k–$1.3M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Asepha — Asepha is an AI clinical decision support (CDS) tool to help healthcare professionals make faster clinical decisions.
- ORA Technologies — E-Commerce, Super App
- THIRUMALS PAPER ARIZONA PVT. LTD. — TRADING PLATFORM OF PULP , PAPER & PACKAGING
V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Belgium, France, United States
Investor stats
- Total investments: 40
- Round size: Seed $3.2M–$50M; Series A $6.6M–$73M; Series B $12M–$88M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $129M in 2021
Portfolio highlights
- Biodol Therapeutics — Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (CyrilRivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.
- Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.
- Corteria Pharmaceuticals — Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure.
Sanofi Ventures invests in top tier biotherapeutic and digital health entrepreneurs who focus on helping patients and transforming the healthcare system.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 113
- Round size: Series A $9M–$81M; Series B $30M–$150M; Series C $30M–$120M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $750M in 2001
Portfolio highlights
- AdvanCell — AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing an innovative pipeline of targeted alpha therapies.
- Lava Therapeutics — Innovation in engaging gamma-delta T cells to potently and precisely fight cancer
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more...Investment focus
- Industry: Software, SaaS, Biotechnology
- Stage:Seed, Series A
- Geography: Denmark, United Kingdom, Iceland
Investor stats
- Total investments: 29
- Round size: Seed $1.2M–$9.1M; Series A $5.6M–$22M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Tame — ABOUT With Tame you can fully customise your virtual events, and make them fun, engaging & exciting to attend.- Apply your branding: Customise your virtual event completely - Personalised Welcome: Personal welcome message when attendees enter - Multiple stages: Broadcast content across multiple stages. - Live streaming: Stream live via anybroadcasting software - Pre-recorded videos: Broadcast pre-recorded videos as if it was live - Breakout sessions: Enable public or private breakout sessions. - Virtual Sponsor booths: Allow attendees to engage with sponsors live. - Customise Chat: Allow for 1:1 chat, group chat or session chat. - 1:1 Video Meetings: Empower social networking virtually.OUR COMPANY We are an experience-centric company, and we believe in the power of great experiences. Our international group of dreamers, creators and rule-breakers passionate about merging design and technology together, enables us to transform that into one truly amazing event platform.OUR PEOPLE The team behind Tame has an aggregated decades long experience of creating events and building products that solve real problems for real people. So, what got us here? Our ambition to change a broken event industry through innovation, customer obsession and a relentless focus on the great experience.
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Spain
Investor stats
- Total investments: 114
- Round size: Series A $6M–$59M; Series B $10M–$125M; Series C $5M–$105M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- AveXis — Discover how Novartis Pharmaceuticals brings innovative medicines to market to enhance health outcomes for patients and offer solutions to healthcare providers.
- Bonum Therapeutics — We have created a new class of antibody-regulated protein therapeutics activated only at disease sites, advancing cancer care and exploring broader indications.
- BlueLight Therapeutics — BlueLight Therapeutics uses a proprietary structure-based platform to discover small molecules against difficult-to-drug targets.BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop novel therapeutic molecules against challenging, high-value drug targets. The company has a passionate and experienced team withunique expertise on developing structural assays across a broad range of target classes.
BankInvest Biomedical Venture makes investments in research-based biotechnology companies in Europe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C
- Geography: Denmark, United Kingdom, France
Investor stats
- Total investments: 9
- Round size: Series B $8M–$8.8M; Series C $6.1M–$14M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
- Nereus Pharmaceuticals — Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent forthe treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
- Resistentia Pharmaceuticals — Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiplesclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.
Physician-led venture capital investing in TechBio, DeepTech Healthcare, and Digital Health.
Show more...Investment focus
- Industry: Health Care, Medical, Wellness
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Sweden
Investor stats
- Total investments: 36
- Round size: Seed $960k–$8.5M; Pre-Seed $655k–$2.5M; Series A $5.2M–$14M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Jude — Science-backed food supplement that makes you feel empowered, not embarrassed.
- Vitrue Health — At Vitrue Health, our mission is to reduce or eliminate the impact that musculoskeletal health issues have on over 40% of the population using cutting edge technology. We believe that the foundation of successful outcomes in musculoskeletal health, at every stage of the pathway, is accurate assessment. Whether it's a desk worker with early stages of neck pain or a patient having a total knee replacement, Vitrue's technology can help.
- Collective Minds Radiology — Collective Minds develops and delivers a cloud-based collaboration platform for healthcare and research with access to data, human and digital expertise.
Executive Agency for SMEs
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed
- Geography: Spain, Switzerland, United Kingdom
Investor stats
- Total investments: 176
- Round size: Seed $55k–$2.2M; Grant $55k–$2.7M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- AGADE — Esoscheletri Agade | Il primo esoscheletro intelligente per lavoratori progettato per ridurre il rischio di disturbi muscolari delle spalle nella movimentazione manuale dei carichi.
- Cyclomics — Discover Cyclomics, pioneers in precision cancer diagnostics using breakthrough consensus-sequencing paired with the Nanopore platform. Our innovative solutions enable ultra-sensitive detection of cancer mutations directly from blood samples, transforming the future of liquid biopsy. Learn more about how Cyclomics is revolutionizing early cancer detection, monitoring, and personalized treatment with cutting-edge, accessible molecular diagnostics.
- Terraplasma — As pioneers in cold plasma science, our team of scientists, engineers, and experts have played a key role in driving research and commercial development. Our groundbreaking work has brought cold plasma technology to companies, public institutions and even private households worldwide.
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Ireland, Singapore
Investor stats
- Total investments: 450
- Round size: Series A $4.5M–$80M; Series B $7M–$107M; Series C $10M–$100M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $182M in 1998
Portfolio highlights
- Thirty Madison — Thirty Madison is a human-first healthcare company, powering access to affordable specialized healthcare through brands like Keeps and Cove.
- CliQr Technologies — CliQr is a leading provider of application-defined cloud management solutions. Offering full lifecycle management delivered in a single, intuitive packaged platform, CliQr enables businesses to easily and efficiently model, deploy and manage one to many applications, users, and clouds.CliQr’s application-defined technology de-couplesapplications from the complexity of hybrid cloud environments, allowing them to securely move, deploy and manage new and existing application across any physical, virtual or cloud environment.CliQr’s patented and patent-pending technology and its global partners help dozens of leading brands in healthcare, manufacturing and technology markets manage their cloud application lifecycles in over 15 different data center, private and public cloud environments.Headquartered in San Jose, California, with locations in Canada, India and Czech Republic, CliQr is backed by Polaris Partners, Foundation Capital, Google Ventures and TransLink Capital. For additional information, visit www.cliqr.com.
- Invivyd — Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patientsand clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with thirdparty contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.
CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Seed, Series B
- Geography: Sweden, Denmark, Germany
Investor stats
- Total investments: 12
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- GLX Analytix — GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
- Swiftly — World's first AI that applies for jobs. Say goodbye to creating CV's, searching and applying for jobs. Let Swiftly do it for you! Welcome to the new age.
- Hugel Control — HUGEL, Inc. strives to be a global company that continuously creates innovative products, promotes universal health, and improves the quality of life through state-of-the-art technology and creativity.
The LS Polaris Innovation Fund aims to accelerate the commercial and therapeutic potential of early stage academic research.
Show more...Investment focus
- Industry: Biotechnology, Medical, Biopharma
- Stage:Series A, Series B
- Geography: United States, Denmark
Investor stats
- Total investments: 6
- Round size: Series A $22M–$83M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Glympse Bio — Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platformtechnology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
- Satellite Bio — Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
- Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
Dansk Erhvervsinvestering is a company that assists individuals with investing.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Geography: Denmark
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Genmab — Genmab is an international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Its primary goal is to improve the lives ofpatients who are in urgent need of new treatment options.
- PremiTech — PremiTech A/S develops systems management software. It offers Performance Guard, a solution that enables IT departments to get real-time measurement of end-user application and infrastructure IT performance in software as a service model. The company also provides Performance Guard CIO Dashboard Module, which provides a view into the ITinfrastructures performance based on grouping by location and application; and Performance Guard Health Check Module that delivers reports on infrastructure components, including applications, mid-tier servers, network and PC Infrastructure for automated, out-of-the-box fast performance documentation, and issue resolution. In addition, it offers monitoring and documentation, and performance monitoring solutions. The company has strategic partnerships with HP, Computer Associates, BMC, VMWare, IBM, and Microsoft. PremiTech A/S was founded in 1999 and is headquartered in Hedehusene, Denmark. As of 2008, PremiTech A/S operates as a subsidiary of CapaSystems A/S.
SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: The Netherlands, United States, Germany
Investor stats
- Total investments: 85
- Round size: Seed $2.8M–$21M; Series A $3.2M–$42M; Series B $2.2M–$88M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — raised $585M in 2016
Portfolio highlights
- Comet Therapeutics — DropCatch.com helps you secure expiring domain names.
- Salvia BioElectronics — Our mission is to give people with migraine a better life. As a pioneer in the field of medical devices, Salvia BioElectronics is passionately committed to empowering people with migraine to reclaim their lives.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 309
- Round size: Series A $6M–$67M; Series B $10M–$120M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Elicit Plant — We work with farmers around the world to meet the challenges of climate change and the impact of water scarcity on field crops.
- l'école — l'école AI is a computer vision-focused development platform. Its objective is to enable humans to use AI with purpose to change the future, beginning with a focus on speeding advances in life sciences using computer vision.
- EndoRon Medical — Endoron Medical develops an endovascular suture, like a device for the effective treatment of an abdominal aortic aneurysm.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Belgium, The Netherlands
Investor stats
- Total investments: 39
- Round size: Series A $15M–$73M; Series B $29M–$89M; Series C $75M–$125M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $241M in 2021
Portfolio highlights
- Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
- Montis Biosciences — Montis Biosciences is develops novel immune-oncology therapeutics targeting the intersection between vascular dysfunction and immune suppression to treat solid tumours.
- Cyteir Therapeutics — Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly ownedlead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
Aprenda a Investir em Startups
Show more...Investment focus
- Industry: Software, Information Technology, Financial Services
- Stage:Seed, Pre-Seed
- Geography: Brazil, United States, Mexico
Investor stats
- Total investments: 535
- Round size: Seed $181k–$5M; Pre-Seed $50k–$600k
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — raised $362k in 2019
Portfolio highlights
- Guapeco — Guapeco provides customized pet insurance services that helps pet parents take care of well-being of their pets through a health plan
- PlayBPO — Plataforma para gestão da operação para quem trabalha com BPO Financeiro
- Elemeno Health — Elemeno Health is an intuitive, cloud-based app, customized to specific needs of your hospital or unit. Streamline training and communication, drive best practices, and empower your staff with just-in-time access to critical information.
LF Investment is the investment arm of The Lauritzen Foundation, which is the parent company of the shipping companies J. Lauritzen (wholly-owned) and DFDS (42,8% holding). LF Investment has holdings in companies in the oil analysis, measuring equipment, software, biotechnology, and real estate sectors.
Show more...Investment focus
- Industry: Medical, Wellness, Health Care
- Geography: Denmark
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Minervax — We are MinervaX. A clinical stage biotech company focused on making a global impact by developing state-of-the-art vaccines.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 26
- Round size: Series A $5.3M–$176M; Series B $5.3M–$45M; Series C $8M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $1.2B in 2022
Portfolio highlights
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- iSTAR Medical — iSTAR Medical is a medtech company delivering breakthrough eye care solutions through minimally-invasive implants with bio-integration.
- HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.
Roland Berger is a Founder of Roland Berger, Munich and has been the Roland Berger GmbH's Honorary Chairman since 2010. Today, Roland Berger has grown to become one of the world's top five strategy consulting firms with 50 offices in 36 countries. The company has a workforce of 2,400 and advises leading international industrial andservice enterprises, as well as public institutions. From the company's foundation in 1967 until 2003, Roland was Chief Executive Officer of the firm, and until 2010 Chairman of the Supervisory Board. Prior to founding his strategy consultancy, Roland was employed as a consultant and ultimately partner at a leading American consulting firm based in Milan and Boston. Roland has been appointed to various expert commissions by several German state governments and the federal government. From 2007 to its dissolution in 2014, Roland was a Member of the High Level Group on Administrative Burdens under the leadership of former Bavarian State Premier Dr. Edmund Stoiber, appointed by the European Commission. Roland is a member of several supervisory boards and advisory councils of national and international companies, foundations and organizations, including Fresenius SE & Co. KGaA (Chairman of the Audit Committee), Bad Homburg; Prime Office REIT-AG, Munich (Chairman of the Supervisory Board); RCS Mediagroup S.p.A.(Vice-President), Milan, Italy. Roland also serves on several international advisory boards, including those of Deutsche Bank AG in Frankfurt, MillerBuckfire in New York and The Blackstone Group in New York. Since 1996 Roland has been a Lecturer and Visiting Professor and since 2000 Honorary Professor for Business Administration and Management Consulting at the Brandenburg Technical University in Cottbus. Furthermore, Roland was appointed a member of the Oxford Martin Commission for Future Generations in 2012. Since 2002, Roland has been on the Business Advisory Council of the State Premier of Saxony-Anhalt and was appointed to the Globalization Council Portugal by the Portuguese President Aníbal Cavaco Silva. Previously, German President Roman Herzog had appointed Roland to the President's Advisory Council for Innovation. Roland has also actively participated in over 20 federal government commissions under Helmut Kohl and Gerhard Schröder. Roland is a member of several supervisory boards and advisory councils of national and international companies, foundations and organizations and invests in many private and listed companies as well as startups. Roland was Honorary Consul General of the Republic of Finland in Bavaria and Thuringia from 1996 to 2015. Roland is Chairman of the Board of Trustees of the Roland Berger Foundation, which he set up personally with an endowment of EUR 50 million. The Roland Berger Foundation is dedicated to the global protection of human dignity and human rights. Each year it confers the Roland Berger Award for Human Dignity. The Foundation also helps gifted children and young people from underprivileged families across Germany and Italy to gain access to the best possible primary and secondary education. Outside work, Roland pursues his interest in modern art and owns a large collection of artworks, mainly by contemporary artists from Europe, the US, South America and China. Roland also loves classical music and supports the Mahler Chamber Orchestra and Bavarian State Opera, among others. Roland loves hiking and cross-country skiing, especially in the Swiss region of Engadin. Roland studied business administration in Munich and Hamburg. (MBA from the Ludwig-Maximilians-Universität, Munich).
Show more...Investment focus
- Industry: Financial Services, Information Services, Apps
- Stage:Series A, Series B
- Geography: Germany, Denmark, Switzerland
Investor stats
- Total investments: 8
- Round size: Series A $4.9M–$30M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- ALOHA — Healthy plant-based foods, snacks & meal replacements. Best organic plant based protein bars, shakes and powders. Nothing artificial. Welcome to ALOHA!
- Balance Re — Scaling the power of ALM
- Loanboox — Loanboox's success speaks for itself: Since the Go-live in September 2016, Loanboox dealt with a volume request over 61 billion Euros. More than 3000 cities and communities as well as institutional investors and banks are active on Loanboox. Loanboox is about to conquer the German, Austrian, French and Dutch market, too. And next step:Digitalisation of capital market.
DigitalDx Ventures is a Silicon Valley Venture firm uniquely positioned to find, support, mentor and grow the outliers in digital healthcare. DDX invests in early stage companies who effectively and efficiently harness the power of artificial intelligence and big data to profoundly impact outcomes in both diagnostics and therapeutics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed
- Geography: United States, Canada, Denmark
Investor stats
- Total investments: 7
- Round size: Series A $3.5M–$18M
- Lead/follow: 57% lead, 43% follow
- Last fund: May invest from a new fund soon — raised $9.7M in 2019
Portfolio highlights
- OxCan — Enabling curative cancer treatment through early detection
- GLX Analytix — GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
- Optina Diagnostics — Optina Diagnostics develops technology for the early detection of disease through the eye.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 79
- Round size: Series A $8.5M–$74M; Series B $14M–$75M; Series C $13M–$143M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- PanOptica — PanOptica is a biopharmaceutical company developing a topical eye drop for the treatment of eye diseases caused by abnormal or leaky blood vessels.
- Galera Therapeutics — Developing novel therapies that have the potential to reduce radiotherapy-induced toxicities and improve the anti-cancer efficacy of radiation therapy
- Reneo Pharmaceuticals — OnKure Therapeutics - Writing the Next Chapter in Precision Medicines for Patients With Cancer
The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation, and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Energy
- Stage:Debt Financing, Post-IPO Debt
- Geography: France, Germany, The Netherlands
Investor stats
- Total investments: 359
- Round size: Post-IPO Debt $18M–$658M; Debt Financing $16M–$384M
- Lead/follow: 80% lead, 20% follow
Portfolio highlights
- Sensible 4 — a Finnish self-driving tech company that has solved a major obstacle in autonomous driving, varying weather. The company develops full-stack autonomous driving software that turns any vehicle into self-driving. The unique technology combines software and information from several different sensors, enabling vehicles to operate in all weatherconditions, including snowfall and fog. In 2022 it will launch the world’s first commercial all-weather software product, Dawn, for SAE level 4 driverless last-mile shuttles.The founders of Sensible 4 have been developing autonomous vehicles since the ‘80s. In February 2020, Sensible 4 secured 7 million dollars in series A funding round from Japanese investors. The technology has won multiple awards, including 1st place in the Dubai World Challenge for Self-Driving Transport 2019 competition.
- Metso Outotec —
- Neuromod Devices — Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'.
Danske Bank is a Nordic universal bank offering a full range of banking services. It was founded 5 October 1871 as Den Danske Landmandsbank, Hypothek- og Vexelbank i Kjøbenhavn (The Danish Farmers' Bank, Mortgage and Exchange Bank of Copenhagen). It is headquartered in Copenhagen, Denmark and is one of the major retail banks in the northernEuropean region with over 5 million retail customers.Danske Bank was number 454 on the Fortune Global 500 list for 2011.
Show more...Investment focus
- Industry: Manufacturing, Energy, Biotechnology
- Stage:Post-IPO Debt, Debt Financing
- Geography: Sweden, Denmark, Finland
Investor stats
- Total investments: 31
- Round size: Post-IPO Debt $24M–$3B; Debt Financing $3.3M–$1.6B
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Fortum — By providing our customers and the Nordic energy system with a supply of reliable energy, we aim to power a world where people, businesses, and nature thrive together. With respect for the environment, decades of expertise and smart solutions, we strive to meet our customers' needs.
- Sitowise — Sitowise is an expert company of over 1,200 personnel that provides its customers the full range of built environment services from planning to expert and digital services. Sitowise is the largest Finnish-owned planning and consulting agency in the construction industry, the leading expert in urban diversified projects, and a pioneer indata-driven management and data modelling.
- Triangle Progression To Employment — Triangle Progression To Employment is an organization that provides supported living and housing services.
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Information Technology, Medical, Software
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 163
- Round size: Seed $544k–$5M; Series A $1.2M–$10M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Fastree3D — Fastree3D imaging sensors help recognize and measure distance to fast moving objects in real-time, enabling driving assistance or autonomous navigation. Fastree3D SA is a fabless semiconductor company, spin-off from EPFL Lausanne, Switzerland founded in September 2013 (UID CHE-291.330.490). The company subsidiary Fastree3D B.V. performs researchwith TU-Delft, Netherlands (KvK 58866973).
- Spyra One — Single Shot Technology | Tactical display | Automatic Refill | Power Shot SpyraTwo - the world's strongest water gun! Start epic water battles with the only water gun in the world that features our patented Single-Shot-Technology, fully automatical pump, a hightech tactical display and the Power Shot for extra impact.
- Arktis Radiation Detectors — Arktis develops and manufactures next generation systems that detect and categorize radiological and nuclear materials to enhance security and operations.
Medical Investor funding in Denmark at a glance
Stats across 159 deals from 132 investors.
Access all 132 investors in Denmark Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical Investors in Denmark investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 132 investors investing in Denmark Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!